Barinthus Biotherapeutics Plc Stock Price To Sales
| BRNS Stock | 0.95 0.02 2.15% |
Barinthus Biotherapeutics plc fundamentals help investors to digest information that contributes to Barinthus Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Barinthus Stock. The fundamental analysis module provides a way to measure Barinthus Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Barinthus Biotherapeutics stock.
Barinthus |
Barinthus Biotherapeutics plc Company Price To Sales Analysis
Barinthus Biotherapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Barinthus Biotherapeutics Price To Sales | 2.69 X |
Most of Barinthus Biotherapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Barinthus Biotherapeutics plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Barinthus Biotherapeutics plc has a Price To Sales of 2.6875 times. This is 87.44% lower than that of the Biotechnology sector and 97.27% lower than that of the Health Care industry. The price to sales for all United States stocks is 76.47% higher than that of the company.
Barinthus Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Barinthus Biotherapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Barinthus Biotherapeutics could also be used in its relative valuation, which is a method of valuing Barinthus Biotherapeutics by comparing valuation metrics of similar companies.Barinthus Biotherapeutics is currently under evaluation in price to sales category among its peers.
Barinthus Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | (53.2 M) | ||||
| Shares Outstanding | 40.23 M | ||||
| Shares Owned By Insiders | 10.98 % | ||||
| Shares Owned By Institutions | 46.19 % | ||||
| Number Of Shares Shorted | 25.37 K | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 2.69 X | ||||
| Revenue | 802 K | ||||
| Gross Profit | (30.12 M) | ||||
| EBITDA | (71.06 M) | ||||
| Net Income | (73.63 M) | ||||
| Total Debt | 12.98 M | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (50.92 M) | ||||
| Short Ratio | 0.51 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 130 | ||||
| Beta | -0.58 | ||||
| Market Capitalization | 40.23 M | ||||
| Total Asset | 214.51 M | ||||
| Retained Earnings | (176.59 M) | ||||
| Working Capital | 144.31 M | ||||
| Net Asset | 214.51 M |
About Barinthus Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Barinthus Biotherapeutics plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Barinthus Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Barinthus Biotherapeutics plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.